MiMedx Group, Inc.
NASDAQ:MDXGBiotechnology
+$0.08 today
- Market cap
- $464.04M
- Beta
- 1.46
- P/E (TTM)
- 17.8
- EPS (TTM)
- $0.21
Volume 1.51M
Average 1.55M
MDXG Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
MiMedx Group, Inc.NASDAQ: MDXG
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 50.1% from a year ago
Cash & equivalents stood at $159.77M at the end of Q1 FY2026, up 50.1% from a year earlier and down 3.8% from the prior quarter. Over 3 fiscal years it compounded at +36.1% a year.
Context
- Cash & equivalents amounted to 51.8% of total assets at the end of Q1 FY2026, up 12.4 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +50.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 166.12M USD
- Year-over-year change
- +59.1%
- 4-year CAGR
- +17.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 166.12M | +59.1% |
| FY2024 | 2024-12-31 | 104.42M | +27.3% |
| FY2023 | 2023-12-31 | 82M | +24.3% |
| FY2022 | 2022-12-31 | 65.95M | -24.3% |
| FY2021 | 2021-12-31 | 87.08M | — |
Cash & Equivalents vs competitors
How MDXG compares with its peers on the latest reported figures
- MDXG's Mar 2026 cash & equivalents of $159.77M is the highest of the 8 companies compared; the peer median is $13.59M.
- Its year-over-year change of +50.1% is the 2nd highest of 8, against a peer median of -24.9%.
- Cash & equivalents amounts to 51.8% of total assets for MDXG, versus a peer median of 17.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $159.77M | +50.1% | +36.1% | 51.8% | |
| Mar 2026 | $92.1M | -16.2% | -2.9% | 17.7% | |
| Mar 2026 | $44.65M | +16.7% | -47.9% | 55.8% | |
| Mar 2026 | $35.94M | -24.9% | +53.2% | 32.8% | |
| Mar 2026 | $13.59M | -34.3% | +22.8% | 19.6% | |
| Mar 2026 | $8.31M | -44.1% | -17.4% | 16.1% | |
| Jun 2026 | $6.96M | -77.4% | +237.0% | 14.3% | |
| Dec 2025 | $6.18M | +736.7% | -23.8% | 5.8% | |
| Peer median (excluding MDXG) | $13.59M | -24.9% | -2.9% | 17.7% | |
Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 87.08M | 65.95M | 82M | 104.42M | 166.12M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 40.35M | 43.08M | 53.87M | 55.83M | 75.71M |
| Inventory | 11.39M | 13.18M | 21.02M | 23.81M | 25.34M |
| Other Current Assets | 3.55M | 4.67M | 1.75M | 2.82M | 10.3M |
| Total Current Assets | 148.52M | 134.2M | 164.26M | 191.89M | 277.47M |
| Property, Plant & Equipment (Net) | 13.86M | 11.26M | 9.11M | 11.55M | 4.71M |
| Goodwill | 19.98M | 19.44M | 19.44M | 19.44M | 19.44M |
| Intangible Assets | 5.38M | 5.85M | 5.26M | 11.63M | 14.16M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 40.78M | 28.31M | 19.6M |
| Other Non-current Assets | 186K | 683K | 205K | 1.11M | 7.27M |
| Total Non-current Assets | 39.41M | 37.23M | 74.79M | 72.03M | 65.18M |
| Total Assets | 187.93M | 171.43M | 239.05M | 263.92M | 342.65M |
| Account Payables | 7.39M | 8.45M | 9.05M | 7.41M | 14.53M |
| Short-term Debt | 0 | 1.44M | 0 | 1M | 2.82M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.91M | 12.81M | 14.61M | 25.45M | 15.85M |
| Total Current Liabilities | 42.36M | 43.56M | 46.01M | 45.6M | 64.27M |
| Long-term Debt | 48.13M | 48.59M | 48.1M | 17.83M | 16.47M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 951K | 2.34M | 2.22M | 2.68M | 2.13M |
| Total Non-current Liabilities | 53M | 53.37M | 50.32M | 25.21M | 21.84M |
| Total Liabilities | 95.35M | 96.92M | 96.33M | 70.81M | 86.11M |
| Common Stock | 113K | 114K | 146K | 147K | 148K |
| Retained Earnings | (161.71M) | (191.91M) | (133.68M) | (91.26M) | (42.68M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 92.58M | 74.51M | 142.72M | 193.11M | 256.55M |
| Total Debt | 53.29M | 52.47M | 48.1M | 24.84M | 22.53M |
| Net Debt | (33.79M) | (13.48M) | (33.9M) | (79.57M) | (143.59M) |
MiMedx Group, Inc.
NASDAQ:MDXG
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.